A Phase 1 trial is enrolling patients with mild to severe dementia from Alzheimer’s disease to test IGC-AD1, an investigational cannabis-based treatment being developed India Globalization Capital (IGC) Pharma, a subsidiary of IGC, according to a recent press release. In the placebo-controlled study, 12 participants will receive the medication over three 14-day periods, with the dose increasing in each period. The study primarily aims to assess the safety of IGC-AD1. Secondary goals include measuring pharmacokinetics…
You must be logged in to read/download the full post.
The post IGC Starts Phase 1 Study of Low-dose Cannabinoid in Alzheimer’s Patients appeared first on BioNewsFeeds.